OLMESARTAN MEDOXOMIL

Post-LOE

olmesartan medoxomil

Aurobindo Pharma

ANDAORALTABLET

Approved

Apr 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (20)

NCT01838850Phase 3Completed

Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy

Started Apr 2013

344 enrolled

Essential Hypertension

NCT01309828Phase 3Completed

Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease

Started Mar 2011

153 enrolled

Safety

NCT01200407N/ATerminated

Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients

Started Jun 2010

615 enrolled

Hypertension

NCT01033071Phase 3Completed

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

Started Jan 2010

1,071 enrolled

Essential Hypertension

NCT00996281Phase 3Completed

Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension

Started Oct 2009

837 enrolled

Essential Hypertension

Worked on OLMESARTAN MEDOXOMIL at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.